Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 87.62
Bid: 93.35
Ask: 93.36
Change: 0.35 (0.401%)
Spread: 0.01 (0.011%)
Open: 87.64
High: 88.78
Low: 87.14
Prev. Close: 88.11
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

STOXX 600 closes at record high on earnings, rate cut optimism

Fri, 10th May 2024 17:21

Rio Tinto considered bid for BHP-target Anglo American -report

*

Green energy production in Italy boosts Enel's Q1 results

*

Medical gear maker Getinge plummets after FDA's safety warning

*

Italy industry output posts unexpected fall in March

May 10 (Reuters) - Europe's main stock index closed at a record high on Friday, on track for its biggest weekly gain since late January, as risk appetite was bolstered by growing bets on interest rate cuts in the region and a strong earnings season.

The pan-European STOXX 600 ended 0.7% higher, with indexes in major economies Germany and France finishing at record highs.

European shares have resumed their record-breaking rally, with the STOXX 600 notching a 3% weekly gain, after investors took a breather in April.

The euphoria around artificial intelligence and monetary policy easing, among others, had sparked bumper gains in the region's stocks since late 2023.

Highlighting Europe's divergence from the U.S. Federal Reserve and boosting equities, the Bank of England hinted at summer rate cuts and Sweden's Riksbank delivered its first cut since 2016 earlier this week.

Minutes from the ECB's April policy meeting showed that policymakers favoured kicking off the monetary policy easing cycle in June, while remaining confident that inflation is on track to fall back to 2% next year.

"Looking beyond June, the path for the bank is anything but clear. The risk of reflation has clearly increased," said Carsten Brzeski, global head of macro at ING Research.

"Any signs of reflation and also stronger economic activity would limit the ECB's room for manoeuvre."

Leading sectoral gains, utilities advanced 1.4%, with Italy's Enel climbing 3.8% following a higher first-quarter core profit. Portugal's largest utility firm EDP climbed 3.9% after a bigger-than-expected jump in first-quarter net profit.

Retailers added 1.5%, with Zalando rising 3.3% after Berenberg upgraded the German online retailer to "buy" from "hold".

Among M&A developments, shares of BBVA and Sabadell were up 1.3% and 0.5%, respectively, as investors assessed the developments around the first hostile banking takeover bid in Spain since the 1980s.

Anglo American advanced 1.4% after a report said mining giant Rio Tinto had considered an offer for the British miner.

Sanofi rose 1.3% after Novavax struck a licensing deal of up to $1.2 billion with French drugmaker for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at double its current market capitalisation.

On the flip side, Getinge slumped 8.8% to the bottom of the STOXX after the U.S. FDA issued a warning on the safety of two of the Swedish medical equipment maker's heart devices.

Symrise shed 1.4% after Berenberg downgraded the German flavour and fragrance maker to "hold" from "buy".

On the data front, Italian industrial output was much weaker than expected in March, extending the pain for the country's struggling manufacturing sector. (Reporting by Ankika Biswas and Johann M Cherian in Bengaluru; Editing by Rashmi Aich, Eileen Soreng and Jane Merriman)

More News
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
23 May 2024 19:21

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.

Read more
22 May 2024 22:59

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 22 (Reuters) -

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.